Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T24557 |
NSC756093
NSC-756093,NSC 756093 |
Others | Others |
NSC756093 可能抑制 GBP1:PIM1 相互作用。 NSC756093 可用于卵巢癌研究。 | |||
T7293 |
EC330
|
Others | Others |
EC330 是一种白血病抑制因子抑制剂。 | |||
T36816 |
S-trityl-L-Cysteine
STLC |
Kinesin | Cytoskeletal Signaling |
S-Trityl-L-cysteine 是别构驱动蛋白Eg5的选择性抑制剂。rityl-L-cysteine 抑制基础 ATPase 活性的IC50为 1 μM,抑制微管激活的 ATPase 活性的IC50为 140 nM。S-Trityl-L-cysteine 显示出抗肿瘤活性。 | |||
T71549 |
RKS-262
|
||
RKS262 is a specific cyclin/CDK inhibitor. RKS262 was identified by structural optimization of Nifurtimox which is currently undergoing phase II clinical trials to treat high-risk neuroblastoma. In a NCI(60) cell-line assay RKS262 exhibited significant cytotoxicity in ovarian cancer cells and a variety of other cell lines exceeding effects of commercial drugs such as cisplatin, 5-FU, cyclophosphamide or sapacitabine. Various leukemia cell-lines were most sensitive (GI(50): ~ 10 nM) while several... | |||
T71252 |
PC-046
|
||
PC-046 is a potent tubulin-binding agent, which was originally identified for development based on selective activity in deleted in pancreas cancer locus 4 (DPC4/SMAD4) deficient tumors. PC-046 has growth inhibitory activity in a variety of tumor types in vitro, and efficacy in SCID mice was shown in human tumor xenografts of MV-4-11 acute myeloid leukemia, MM.1S multiple myeloma, and DU-145 prostate cancer. Pharmacokinetic studies demonstrated relatively high oral bioavailability (71 %) with di... |